MESO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 01:01):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
今日成交量	238 356
平均成交量	2.33M
市值	869.05M
EPS	$0 ( 2024-03-25 )
下一个收益日期	( $-0.320 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.93
ATR14	$0.0300 (0.39%)

音量相关性

長: 0.02 (neutral)

短: 0.87 (strong)

Signal:(53.727) Same movement expected

Mesoblast Limited 相关性

10 最正相关
PFSW	0.949
LABP	0.944
DSGN	0.941
NN	0.94
CTIC	0.936
PRVB	0.93
CDXC	0.927
PESI	0.927
IDN	0.92
SCTL	0.919

10 最负相关
LIAN	-0.939
SBNYP	-0.928
LUCD	-0.923
LUNA	-0.922
NOVN	-0.912
NLSP	-0.909
AEY	-0.908
PRFT	-0.908
AZ	-0.907
EZGO	-0.905

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Mesoblast Limited 相关性 - 货币/商品

0.28
( neutral )

0.75
( moderate )

0.00
( neutral )

0.73
( moderate )

-0.49
( neutral )

0.44
( neutral )

Mesoblast Limited 财务报表

Annual	2023
营收:	$7.50M
毛利润:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2023
营收:	$7.50M
毛利润:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2022
营收:	$10.21M
毛利润:	$-20.55M (-201.21 %)
EPS:	$-1.330

FY	2021
营收:	$7.46M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.817

Financial Reports:

No articles found.

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.